Cargando…

Population Pharmacokinetics of Busulfan and Its Metabolite Sulfolane in Patients with Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation

For patients with myelofibrosis, allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative treatment to date. Busulfan-based conditioning regimens are commonly used, although high inter-individual variability (IIV) in busulfan drug exposure makes individual dose select...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dadkhah, Adrin, Wicha, Sebastian Georg, Kröger, Nicolaus, Müller, Alexander, Pfaffendorf, Christoph, Riedner, Maria, Badbaran, Anita, Fehse, Boris, Langebrake, Claudia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9229330/ https://www.ncbi.nlm.nih.gov/pubmed/35745718 http://dx.doi.org/10.3390/pharmaceutics14061145

Ejemplares similares

Evaluation of the Robustness of Therapeutic Drug Monitoring Coupled with Bayesian Forecasting of Busulfan with Regard to Inaccurate Documentation
por: Dadkhah, Adrin, et al.
Publicado: (2021)

Donor Lymphocyte Infusion and Molecular Monitoring for Relapsed Myelofibrosis After Hematopoietic Cell Transplantation
por: Gagelmann, Nico, et al.
Publicado: (2023)

Digital-droplet PCR assays for IDH, DNMT3A and driver mutations to monitor after allogeneic stem cell transplantation minimal residual disease of myelofibrosis
por: Mannina, Daniele, et al.
Publicado: (2022)

Use of ropeginterferon in inducing graft versus myelofibrosis effect in post‐transplant myelofibrosis relapse
por: Srivastava, Barnali, et al.
Publicado: (2023)

Case Report: Lymphodepletion followed by CAR-T cell therapy with Idecabtagen vicleucel in a patient with severe renal impairment
por: Marquard, Franziska, et al.
Publicado: (2023)

Reduced intensity hematopoietic stem cell transplantation for accelerated-phase myelofibrosis
por: Gagelmann, Nico, et al.
Publicado: (2022)

Digital PCR Assays for Precise Quantification of CD19-CAR-T Cells after Treatment with Axicabtagene Ciloleucel
por: Fehse, Boris, et al.
Publicado: (2020)

5-Azacytidine Promotes an Inhibitory T-Cell Phenotype and Impairs Immune Mediated Antileukemic Activity
por: Stübig, Thomas, et al.
Publicado: (2014)

High Molecular and Cytogenetic Risk in Myelofibrosis Does Not Benefit From Higher Intensity Conditioning Before Hematopoietic Cell Transplantation: An International Collaborative Analysis
por: Gagelmann, Nico, et al.
Publicado: (2022)

Stem cell transplantation in myelofibrosis
por: Kröger, Nicolaus
Publicado: (2018)

Accurate In-Vivo Quantification of CD19 CAR-T Cells after Treatment with Axicabtagene Ciloleucel (Axi-Cel) and Tisagenlecleucel (Tisa-Cel) Using Digital PCR
por: Badbaran, Anita, et al.
Publicado: (2020)

Replacement of hematopoietic system by allogeneic stem cell transplantation in myelofibrosis patients induces rapid regression of bone marrow fibrosis
por: Kröger, Nicolaus, et al.
Publicado: (2012)

Effect of pharmacokinetics and pharmacogenomics in adults with allogeneic hematopoietic cell transplantation conditioned with Busulfan
por: Seydoux, Claire, et al.
Publicado: (2023)

Digital PCR Panel for Sensitive Hematopoietic Chimerism Quantification after Allogeneic Stem Cell Transplantation
por: Stahl, Tanja, et al.
Publicado: (2016)

Impact of busulfan pharmacokinetics on outcome in adult patients receiving an allogeneic hematopoietic cell transplantation
por: Seydoux, Claire, et al.
Publicado: (2022)

Population pharmacokinetics of oral high-dose busulfan in adult patients undergoing hematopoietic stem cell transplantation
por: Hadjibabaie, M., et al.
Publicado: (2011)

External Evaluation of Population Pharmacokinetic Models of Busulfan in Chinese Adult Hematopoietic Stem Cell Transplantation Recipients
por: Huang, Huiping, et al.
Publicado: (2022)

Allogeneic stem cell transplant for multiple myeloma & myelofibrosis with split-dose busulfan, fludarabine & cyclophosphamide
por: Trunk, Andrew D., et al.
Publicado: (2023)

Implementation and Cross-Validation of a Pharmacokinetic Model for Precision Dosing of Busulfan in Hematopoietic Stem Cell Transplanted Children
por: Goutelle, Sylvain, et al.
Publicado: (2022)

Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis
por: Robin, Marie, et al.
Publicado: (2019)

Innovative strategies to improve hematopoietic stem cell transplant outcomes in myelofibrosis
por: Perram, Jacinta, et al.
Publicado: (2022)

Influence of glutathione S-transferase gene polymorphisms on busulfan pharmacokinetics and outcome of hematopoietic stem-cell transplantation in thalassemia pediatric patients
por: Ansari, M, et al.
Publicado: (2016)

Factors limiting sulfolane biodegradation in contaminated subarctic aquifer substrate
por: Kasanke, Christopher P., et al.
Publicado: (2017)

P1024: IMPACT OF TP53 IN MYELOFIBROSIS UNDERGOING STEM CELL TRANSPLANTATION
por: Gagelmann, N., et al.
Publicado: (2022)

Minimal Residual Disease Diagnostics and Chimerism in the Post-Transplant Period in Acute Myeloid Leukemia
por: Bacher, Ulrike, et al.
Publicado: (2011)

Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trial
por: Seydoux, Claire, et al.
Publicado: (2020)

Precision dosing of intravenous busulfan in pediatric hematopoietic stem cell transplantation: Results from a multicenter population pharmacokinetic study
por: Ben Hassine, Khalil, et al.
Publicado: (2021)

Antitumor Activity and Neutrophil‐selective Hematopoietic Toxicity of Busulfan Analogs in Mice
por: Kato, Taketoshi, et al.
Publicado: (1988)

Phenytoin as seizure prophylaxis in hematopoietic stem cell transplantation with busulfan conditioning
por: Germeraad, R. S., et al.
Publicado: (2022)

High-Voltage Sulfolane Plasticized UV-Curable Gel Polymer Electrolyte
por: Wang, Shiqi, et al.
Publicado: (2019)

Temperature-Related Corrosion Resistance of AISI 1010 Carbon Steel in Sulfolane
por: Kubisztal, Julian, et al.
Publicado: (2020)

Health Impact Assessment of Sulfolane on Embryonic Development of Zebrafish (Danio rerio)
por: Shah, Soham M., et al.
Publicado: (2019)

Treosulfan-Based Conditioning Regimen for Second Allograft in Patients with Myelofibrosis
por: Atagunduz, Isik Kaygusuz, et al.
Publicado: (2020)

Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia
por: Pidala, Joseph, et al.
Publicado: (2010)

State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019
por: McLornan, Donal P., et al.
Publicado: (2019)

Successful hematopoietic stem cell transplantation with reduced dose of busulfan for Omenn syndrome
por: Matsukawa, Yukihiro, et al.
Publicado: (2022)

Allogeneic hematopoietic stem-cell transplantation for myelofibrosis
por: Zhang, Lining, et al.
Publicado: (2020)

Crystal structure of cis-tetraaquadichloridocobalt(II) sulfolane disolvate
por: Boudraa, Mhamed, et al.
Publicado: (2015)

Refined Force Field for Liquid Sulfolane with Particular Emphasis to Its Transport Characteristics
por: Mukherji, Srimayee, et al.
Publicado: (2020)

Supporting data for characterization of the busulfan metabolite EdAG and the Glutaredoxins that it adducts
por: Scian, Michele, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_cd8ip36efrncajalb14vdisj24